Halozyme Therapeutics director Matthew L. Posard reports sale of 5,000 common shares for $482,146.60
HALO•Director Matthew L. Posard sold 5,000 Halozyme Therapeutics shares on Nov. 18, 2026, for a reported total of $482,146.60, leaving him with 48,609 shares.
1. Share sale
Posard sold 5,000 common shares on Nov. 18, 2026: 3,400 shares at $96.173 each and 1,600 at $96.974 each. He directly owned 48,609 shares after the transactions.




